3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Skin Neoplasms
1
Neoplasms
1
Melanoma
1
Carcinoma, Merkel Cell
1
Carcinoma, Basal Cell
1
Carcinoma
1
Interventions
pembrolizumab
16
Nivolumab
15
Ipilimumab
12
cemiplimab
10
aldesleukin
6
Interleukin-2
6
Cyclophosphamide
6
fludarabine
5
fludarabine phosphate
4
encorafenib
4
binimetinib
4
Blood Specimen Collection
4
avelumab
3
Sirolimus
3
trametinib
2
spartalizumab
2
lifileucel
2
dabrafenib
2
atezolizumab
2
Vemurafenib
2
Surgical Procedures, Operative
2
Specimen Handling
2
Radiotherapy
2
Prednisone
2
Niacinamide
2
Exercise
2
Everolimus
2
Dermoscopy
2
Biopsy
2
urelumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Skin Neoplasms
×
MAPRE1 protein, human
×
1 year
×
Clear all
NCT04349436
2026-04-22
ARTACUS
Replimune, Inc.
Phase 1/2
Active not recruiting
69 enrolled